Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Kuter DJ, et al. Among authors: cunningham i. N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297. N Engl J Med. 2022. PMID: 35417637 Clinical Trial.
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
McQuilten Z, Heritier S, Fox L, Fox V, Young L, Blombery P, Cunningham I, Curnow J, Higgins A, Hiwase DK, Filshie R, Firkin F, Lacaze P, Mason K, Mills AK, Pepperell D, Patil S, Stevenson W, Szer J, Waters N, Wilson K, Ting S, Wood E. McQuilten Z, et al. Among authors: cunningham i. BMJ Open. 2024 Jan 18;14(1):e076246. doi: 10.1136/bmjopen-2023-076246. BMJ Open. 2024. PMID: 38238183 Free PMC article.
A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis.
Mollee P, Tiley C, Cunningham I, Moore J, Prince HM, Cannell P, Gibbons S, Tate J, Paul S, Mar Fan H, Gill DS. Mollee P, et al. Among authors: cunningham i. Br J Haematol. 2012 Jun;157(6):766-9. doi: 10.1111/j.1365-2141.2012.09080.x. Epub 2012 Mar 6. Br J Haematol. 2012. PMID: 22390735 Free article. Clinical Trial. No abstract available.
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.
Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF. Kenealy M, et al. Among authors: cunningham i. Haematologica. 2019 Apr;104(4):700-709. doi: 10.3324/haematol.2018.201152. Epub 2018 Dec 13. Haematologica. 2019. PMID: 30545923 Free PMC article. Clinical Trial.
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group. Bradstock KF, et al. Among authors: cunningham i. J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3. J Clin Oncol. 2017. PMID: 28368672 Clinical Trial.
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.
Trotman J, Trinh J, Kwan YL, Estell JA, Fletcher J, Archer K, Lee K, Foo K, Curnow J, Bianchi A, Wignall L, Verner E, Gasiorowski R, Siedlecka E, Cunningham I. Trotman J, et al. Among authors: cunningham i. Intern Med J. 2017 May;47(5):542-548. doi: 10.1111/imj.13302. Intern Med J. 2017. PMID: 27753208
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ. Li Z, et al. Among authors: cunningham i. Haematologica. 2018 Apr;103(4):655-665. doi: 10.3324/haematol.2017.178384. Epub 2018 Jan 19. Haematologica. 2018. PMID: 29351987 Free PMC article.
Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
Lo TH, Abadir E, Gasiorowski RE, Kabani K, Ramesh M, Orellana D, Fromm PD, Kupresanin F, Newman E, Cunningham I, Hart DNJ, Silveira PA, Clark GJ. Lo TH, et al. Among authors: cunningham i. PLoS One. 2019 May 10;14(5):e0216368. doi: 10.1371/journal.pone.0216368. eCollection 2019. PLoS One. 2019. PMID: 31075107 Free PMC article.
A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset.
Bryant C, Fromm PD, Kupresanin F, Clark G, Lee K, Clarke C, Silveira PA, Suen H, Brown R, Newman E, Cunningham I, Ho PJ, Gibson J, Bradstock K, Joshua D, Hart DNj. Bryant C, et al. Among authors: cunningham i. Immunol Cell Biol. 2016 May;94(5):447-57. doi: 10.1038/icb.2015.116. Epub 2016 Jan 21. Immunol Cell Biol. 2016. PMID: 26791160
224 results